ZVRA Stock Forecast & Price Target

Zevra Therapeutics is currently undervalued, and our analysis indicates that there is significant potential for the stock to increase in value. This is due to the company's strong commercialization of its product, MIPLYFFA, for the treatment of Niemann-Pick disease type C. With a current estimated market size of 300-350 patients in the US alone, and a potential market of ~900 patients globally, Zevra is well-positioned to capture a meaningful market share. The recent increase in enrollments, including patients outside of the initial target market, demonstrates the company's ability to expand its reach and tap into a larger patient pool. Furthermore, the company's healthy financials, with a substantial amount of cash and no debt, provide it with the flexibility to invest in its current and future pipeline of rare disease therapeutics. Additionally, Zevra's ongoing clinical trial for its candidate celiprolol, targeting patients with Vascular Ehler-Danlos syndrome, shows potential for growth and diversification of its product portfolio. However, there are some risks involved, such as potential clinical or regulatory setbacks, competition, and the need for additional capital. Overall, our outlook on Zevra Therapeutics is positive, given its strong commercial performance, expanding patient reach, and healthy

Zevra Therapeutics is at risk of being impacted by the recent approval of a competitor's therapy, as patients and payers may prefer the competitor over Zevra's already-marketed product for NPC. Additionally, ongoing volatility in non-French EAP reimbursements could negatively affect near-term revenue estimates for Zevra's late-stage pipeline drug, miplyffa. The company's decision to maintain access for potential patients during the EMA re-examination of arimoclomol MAA may provide short-term safety, but failure of the drug in a pivotal study would limit future development options.